Remdac™ (Remdesivir) from Zydus now more affordable at Rs. 899

In a significant move Zydus has made its brand of Remdesivir, Remdac™ more affordable at Rs. 899 for a 100 mg lyophilized injection. Remdac™ which was launched in August 2020 at Rs. 2800, continues to be India's most economical brand of Remdesivir and a critical drug in the treatment of COVID-19. This move to further revise the prices will go a long way in helping patients during these critical times.

Speaking on the development Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, "Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people. Remdac™ has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug."

In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19. The API for the drug has been developed and manufactured at the group's API manufacturing facilities in Gujarat.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.426.3 as compared to the previous close of Rs. 431.05. The total number of shares traded during the day was 82177 in over 1308 trades.

The stock hit an intraday high of Rs. 436.05 and intraday low of 426.3. The net turnover during the day was Rs. 35526319.

Source : Equity Bulls

Keywords